Michael Jirovec – Trademark Portfolio
Entity Type: 01
Michael Jirovec holds 19 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 14 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 4 Nice Classification classes. Currently, 3 trademarks are registered and 7 are pending. Notable registered marks include ARSYNIST, HUMASLIN, and CONDEMNED. The owner is based in Brooklyn, NY.
20 Fane Court
Brooklyn, NY 11209
Showing of trademarks Trademarks
Trademark Classifications
Michael Jirovec's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Michael Jirovec have?
Michael Jirovec has 19 U.S. trademarks filed with the USPTO. Of these, 3 registered, 7 pending, 8 abandoned, 1 cancelled.
What trademark classes does Michael Jirovec file in?
Michael Jirovec files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 3 (Cosmetics & Cleaning), Class 25 (Clothing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Michael Jirovec's most well-known trademarks?
Michael Jirovec's registered trademark portfolio includes well-known marks such as ARSYNIST, HUMASLIN, and CONDEMNED. These are among 3 currently registered trademarks in the portfolio.
What is Michael Jirovec's trademark registration success rate?
Michael Jirovec has a 25% trademark registration rate, with 3 out of 12 resolved applications resulting in successful registration. Currently, 7 applications are pending review.